Vascular Endothelial Growth Factor (121), Sf9 Protein
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Vascular Endothelial Growth Factor (121), Sf9 Protein is a recombinant cytokine.
Documents del producto
Product specifications
| Category | Proteins and Peptides |
| Immunogen Target | VEGF (121a.a.) Sf9 |
| Origin | Human |
| Conjugation | Unconjugated |
| Expression | Recombinant |
| Purity | > 95% (SDS-PAGE) |
| Size 1 | 2 µg |
| Size 2 | 10 µg |
| Size 3 | 1 mg |
| Form | Lyophilized |
| Tested Applications | SDS-PAGE |
| Availability | Shipped within 5-10 working days. |
| Dry Ice | No |
| UniProt ID | P15692 |
| Alias | L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor |
| Background | Protein VEGFA |
| Status | RUO |
| Note | This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use. |
Descripción
VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases
Related Products
Goat VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit
Ver Producto
Guinea pig VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit
Ver Producto
VEGFA antibody
VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1(MVCD1). VEGFA has 13 isoforms with MW 16kd to 45kd. Some isoforms has homodimer form, such as VEGFA189(38kd), VEFGA110(34kd). VEGFA is a 34kd to 42kd, dimeric, disulfide-bound glycoprotein. VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids(PMID:15602010).
Ver Producto